| Whitney L Klas, APNP | |
|
2793 Lineville Rd, Green Bay, WI 54313-7152 | |
| (920) 496-4700 | |
| Not Available |
| Full Name | Whitney L Klas |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 2793 Lineville Rd, Green Bay, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164093993 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 11057-33 (Wisconsin) | Primary |
| Entity Name | Prevea Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306869276 PECOS PAC ID: 0042123150 Enrollment ID: O20031106000034 |
News Archive
When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
› Verified 6 days ago
| Entity Name | St. Nicholas Hospital-sisters Of The Third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275799413 PECOS PAC ID: 8325931652 Enrollment ID: O20040202001172 |
News Archive
When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
› Verified 6 days ago
| Entity Name | St Clare Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851477913 PECOS PAC ID: 0446211395 Enrollment ID: O20041023000037 |
News Archive
When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
› Verified 6 days ago
| Entity Name | St Vincent Hospital-hospital Sisters-third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285613638 PECOS PAC ID: 5799694675 Enrollment ID: O20080620000423 |
News Archive
When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Whitney L Klas, APNP Po Box 19070, Green Bay, WI 54307-9070 Ph: (920) 496-4700 | Whitney L Klas, APNP 2793 Lineville Rd, Green Bay, WI 54313-7152 Ph: (920) 496-4700 |
News Archive
When breast cancer advances, the patient doesn't have the luxury of time. Finding the right type of chemotherapy as quickly as possible is a critical factor for the patient's success and, until now, predicting the patient's sensitivity to chemotherapy has often been a shot in the dark.
Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005.
Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
› Verified 6 days ago
Dr. Rachael E. Vanden Langenberg, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3263 Eaton Rd, Green Bay, WI 54311 Phone: 920-433-6700 | |
Bradley Jay Fedderly, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2845 Greenbrier Rd, Green Bay, WI 54311 Phone: 920-288-8100 Fax: 414-762-4225 | |
Amy M Romandine Kratz, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1727 Shawano Ave, Green Bay, WI 54303 Phone: 920-496-4700 | |
Barbara H Franck, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 840 Challenger Dr Ste 191, Green Bay, WI 54311 Phone: 920-412-9737 Fax: 920-489-2247 | |
Matthew Krueger Jenson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 124 Siegler St, Green Bay, WI 54303 Phone: 920-494-9661 Fax: 920-496-3792 | |
Trent J Auguston, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3021 Voyager Dr, Green Bay, WI 54311 Phone: 920-496-4700 | |
Julie A Magnin, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2253 W Mason St, Green Bay, WI 54303 Phone: 920-327-7300 Fax: 920-327-7301 |